|
Calprotectin (μg/mL)
|
2.38 (1.79–3.16; < 0.0001)
|
2.74 (1.71–4.41; < 0.0001)
|
|
Power Doppler score, 0–66
|
1.31 (1.18–1.45; < 0.0001)
| |
|
TNFi trough serum levels (μg/mL)
|
0.47 (0.26–0.88; 0.018)
|
0.36 (0.10–1.30; 0.120)
|
|
DAS-ESR
|
2.10 (0.72–6.18; 0.175)
| |
|
Time-to-remission (months)
|
1.17 (1.11–1.23; < 0.0001)
| |
|
Time-in-remission (months)
|
0.98 (0.97–1.00; 0.087)
| |
|
Female gender
|
1.25 (0.38–4.15; 0.716)
| |
|
Disease duration (months)
|
1.02 (0.96–1.08; 0.510)
| |
|
Diagnosis, RA/PsA
|
2.39 (0.72–7.93; 0.155)
|
0.80 (0.10–6.30; 0.832)
|
|
Age (years)
|
0.98 (0.94–1.03; 0.535)
| |
|
Monotherapy
|
0.36 (0.10–1.33; 0.125)
|
0.51 (0.08–3.35; 0.484)
|
|
Steroids
|
3.12 (1.02–10.1; 0.046)
|
0.22 (0.04–1.21; 0.082)
|
